Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Quest Diagnostics Inc (DGX) vs Victoria's Secret & Co (VSXY) Price & Performance

Quest Diagnostics IncTrade
Victoria's Secret & CoTrade

Price performance (Past 24H)

Key statistics

Quest Diagnostics Inc vs Victoria's Secret & Co — how do they compare? Quest Diagnostics Inc trades at $231.66 (market cap $25.48B), while Victoria's Secret & Co trades at $82.76 (market cap $6.91B). The key difference: Quest Diagnostics Inc is far larger — about 3.7× Victoria's Secret & Co's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Victoria's Secret & Co pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Victoria's Secret & Co for 34 Days on average.

DGXVSXY
Market Cap
$25.48B$6.91B
Volume
941,8661,346,928
Sector
HealthConsumer Cyclical
52-Week High
$247.45$99.97
52-Week Low
$173.49$28.25
Typical Hold Time
56 Days34 Days
Enterprise Value
$31.23B$9.29B
Dividend Yield
1.49%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Quest Diagnostics Inc

Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.

The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.

Victoria's Secret & Co

Victoria's Secret (VSXY) trades at $81.83, down 4.62% today, but maintains strong technical momentum with a bullish moving average signal. The company shows improving fundamentals with three consecutive quarterly earnings beats and a robust 45.27% ROE. Recent news highlights the fashion show expansion and omnichannel growth strategy driving international sales momentum. Cash flow projections for 2026 show significant improvement to $334M net cash flow, indicating stronger financial health ahead.

The stock presents a compelling opportunity with 60% analyst buy ratings and an $86.80 consensus target offering 6% upside. However, elevated valuation multiples and recent margin pressure require careful monitoring. The company's Path to Potential initiative shows promising traction, but execution risks and competitive retail pressures remain key considerations for investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DGX

No sentiment data available yet.

VSXY
96% Buy4% Sell
Avg holding period · 34 Days

About Quest Diagnostics Inc

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Read more on DGX →

About Victoria's Secret & Co

Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.

Read more on VSXY →